Extrapleural hematoma as a complication following thoracotomy for pulmonary lobectomy.

Extrapleural hematoma as a complication following thoracic surgery is rare. We report a case of an extrapleural hematoma following pleural lobectomy that resolved completely with nonsurgical treatment. A 63-year-old woman underwent left lower lobectomy for lung cancer through a left posterolateral thoracotomy.

A case of primary pulmonary hypertension with pulmonary tumor.

A 64-year-old female with a 9-year history of primary pulmonary hypertension developed a solid pulmonary tumor. Partial lung resection was planned for diagnosis. Although prostacyclin was increased to 8 ng/kg/min, she did not tolerate the decubitus position and one-lung ventilation, and her pulmonary arterial pressure rose to 110/45 mmHg.

Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231.

Although the p53 anti-oncogene is an important target for gene therapy of cancer, some cancers are resistant to p53 gene transfer. For this reason, it is important to find effective drugs to enhance cytotoxic effects of p53 gene transfer. Recent reports demonstrated that some histone deacetylase inhibitors in combination with p53 gene therapy induced apoptosis in certain cancer cells more efficiently than p53 gene therapy alone.

Simultaneous resection of bilateral intralobar and extralobar pulmonary sequestrations with video-assisted thoracoscopic surgery.

The term pulmonary sequestration is applied to a pulmonary lobe or portion of a lobe that is supplied by an anomalous systemic artery and drain either into the systemic or pulmonary veins. The conditions are divided into intralobar pulmonary sequestration, in which the sequestration is situated inside the visceral pleura of a normal lobe, and extralobar sequestration, in which the sequestration is surrounded by its own pleura. Most sequestrations are unilateral; bilateral sequestrations are rare.

Survival and prognostic factors in resected cN2-pN0 non-small cell lung cancer.

This study retrospectively examined the records of patients with clinical N2 (cN2) stage non-small cell lung cancer (NSCLC) who were surgically treated but who actually had pathologic N0 (pN0) stage disease. From 1982 to 1997, 94 patients with cN2 NSCLC underwent surgery. Forty-five patients proved to have pN0 disease, with an overall 5-year survival rate of 67.